Market News & Trends
Immunocore Announces Dosing of First Patient With ImmTAV Bispecific for HIV
Immunocore Holdings plc recently announced the dosing of the first patient in the first-in-human Phase 1 clinical trial of IMC-M113V, a new class of bispecific…
MediWound Announces Positive Initial Data From Phase 1/2 Study for the Treatment of Basal Cell Carcinoma
MediWound Ltd. recently announced positive initial data from 11 patients in its ongoing open-label Phase 1/2 study of MW005 for the treatment of low-risk Basal…
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Acer Therapeutics & Relief Therapeutics Announce China National Intellectual Property Administration Issued Utility Model Patent
Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics recently announced the China National Intellectual Property Administration (CNIPA) issued Electronic Patent Certificate ZL202122004991.9 on May…
Sirio Pharma Announces Agreement to Acquire Best Formulations
Sirio Pharma Co., Ltd. – the global nutraceutical contract development and manufacturing organization (CDMO) – and Best Formulations, Inc. recently announced that they have entered…
Absci Enters Multi-Program Collaboration With Emerging Biotech Partner
Absci Corporation recently announced it has entered into a collaboration agreement with an undisclosed biotech partner. The partner is a stealth-mode company, led by….
Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase 3 Part A Clinical Trial
Akari Therapeutics, Plc recently announced a patient has completed the course of investigational nomacopan treatment in the open-label, multi-center Phase 3 Part A clinical trial in pediatric hematopoietic stem….
Insilico Medicine Identified Multiple New Targets for ALS Using its AI-Driven Target Discovery Engine
Insilico Medicine recently announced the company has identified multiple unreported potential therapeutic targets for amyotrophic lateral sclerosis (ALS), using its proprietary AI-driven target discovery engine….
Alvotech Initiates Patient Study for Proposed Biosimilar for Eylea
Alvotech recently announced the initiation of the company’s confirmatory clinical study for AVT06 (aflibercept), a biosimilar candidate to Eylea…..
PDS Biotech Announces Efficacy & Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head & Neck Cancer
PDS Biotechnology Corporation recently announced a poster presentation of preliminary data from its ongoing Phase 2 VERSATILE-002 clinical trial at the American Society of Clinical…
VectorBuilder to Invest $30 million to Build the World’s First AAV Superbank
VectorBuilder Inc. recently announced its plan to invest $30 million to build an AAV Superbank for the research and drug discovery community. The company will…
Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3
Immutep Limited recently announced the grant of a new patent (number 7074341) titled Anti-LAG-3 Antibodies by the Japanese Patent Office. This new Japanese patent follows…
Protega Pharmaceuticals LLC Announces Commercialization of Oxycodone Hydrochloride Tablets CII in the US
Protega Pharmaceuticals LLC recently announced the commercial launch of RoxyBond (oxycodone) immediate-release (IR) tablets in the US. RoxyBond was approved by the US FDA as…
VUMC & Roivant Social Ventures Announce Collaboration to Develop Therapies for Underserved Populations
Vanderbilt University Medical Center (VUMC) and Roivant Social Ventures (RSV) recently announced an intention to collaborate in developing therapies for traditionally underserved populations and diseases.…
MilliporeSigma Launches BioContinuum Seed Train Platform for Intensified Upstream Processes
MilliporeSigma, the US and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, recently announced at the ESACT meeting…
Mogrify & Astellas Announce Collaboration to Conduct Research on In Vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss
Mogrify Limited and Astellas Pharma Inc. recently announced they have executed a collaborative research agreement on in vivo regenerative medicine approaches to….
Codiak BioSciences & CEPI Partner to Develop Broadly Protective Betacoronavirus Vaccine
CEPI, the Coalition for Epidemic Preparedness Innovations, and Codiak BioSciences recently announced the latest funding award under CEPI’s US $200 million program to advance the development of vaccines that provide broad protection against….
Fastox to Present its Long-Lasting Botulinum Toxin LAST Technology
Swiss biotech Fastox Pharma will present for the first time its groundbreaking long-lasting botulinum toxin LAST technology at the leading conference on neurotoxins from July…
Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial
Fulcrum Therapeutics, Inc. recently announced the first patient has been dosed in REACH, a Phase 3 clinical trial designed to evaluate the safety and efficacy…
DFE Pharma Expands its Inhalation Portfolio With New Launch
DFE Pharma recently announced the expansion of its Dry Powder Inhalation (DPI) portfolio with the launch of Lactohale 400. The addition of Lactohale 400 further enhances the completeness of DFE Pharma’s portfolio of inhalation-grade lactose…..
